(paliperidone palmitate)
This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
INVEGA SUSTENNA® (paliperidone palmitate)
Medical Information
INVEGA SUSTENNA - Dosing - Dosing Overview
Last updated : 11/11/2024
SPECIFIC RESPONSE
For patients who have never taken oral paliperidone or oral or injectable risperidone, it is recommended to establish tolerability with oral paliperidone or oral risperidone prior to initiating treatment with INVEGA SUSTENNA. Each injection must be administered only by a healthcare professional.1
Initiation:
- The initiation regimen for INVEGA SUSTENNA was designed to rapidly attain steady-state paliperidone concentrations when initiating therapy without the use of oral antipsychotic supplementation.
- To avoid a missed dose, patients may be given the second initiation dose 4 days before or after the one-week time point.
Maintenance:
- Administered 5 weeks after the first injection.
- The recommended maintenance dose for treatment of schizophrenia is 117 mg. Some patients may benefit from lower or higher maintenance doses within the additional available strengths (39 mg, 78 mg, 156 mg, and 234 mg).
- There is no recommended monthly maintenance dose for patients with schizoaffective disorder; adjust dose based on tolerability and/or efficacy using available strengths. The 39 mg strength was not studied in the long-term schizoaffective disorder study.
- Adjustment of the maintenance dose may be made monthly. Adjust dose based on tolerability and/or efficacy using available strengths.
- When making dose adjustments, the prolonged-release characteristics of INVEGA SUSTENNA should be considered, as the full effect of the dose adjustment may not be evident for several months.
- To avoid a missed monthly dose, patients may be given the paliperidone palmitate injection up to 7 days before or after the monthly time point.
aTo help attain therapeutic concentrations rapidly
bRecommended monthly maintenance dose
BMI, body mass index; ER, extended release; IM, intramuscular; PK, pharmacokinetic.
References
Show Hide
1. INVEGA SUSTENNA [(paliperidone palmitate) Extended-Release Injectable Suspension] [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc; https://imedicalknowledge.veevavault.com/ui/approved_viewer?token=7994-54c7ff1c-5e50-4845-a605-24e8c5104cd7.
